Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Daiichi Sankyo
Deloitte
Farmers Insurance
Merck
Covington

Generated: April 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FASLODEX

« Back to Dashboard

Clinical Trials for FASLODEX

Trial ID Title Status Sponsor Phase Summary
NCT00006903 Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer Active, not recruiting AstraZeneca Phase 2 RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells. PURPOSE: This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer.
NCT00006903 Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer Active, not recruiting National Cancer Institute (NCI) Phase 2 RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells. PURPOSE: This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer.
NCT00006903 Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer Active, not recruiting Gynecologic Oncology Group Phase 2 RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells. PURPOSE: This phase II trial is studying fulvestrant to see how well it works in treating patients with recurrent, persistent, or metastatic endometrial cancer.
NCT00010153 ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer Terminated Breast International Group Phase 3 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 before surgery may block the uptake of estrogen by the tumor cells and prevent metastases. It is not yet known if ICI 182780 is effective in preventing breast cancer metastases. PURPOSE: Randomized phase III trial to study the effectiveness of ICI 182780 given before surgery in treating women who have stage I or stage II primary breast cancer.
NCT00010153 ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer Terminated European Organisation for Research and Treatment of Cancer - EORTC Phase 3 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 before surgery may block the uptake of estrogen by the tumor cells and prevent metastases. It is not yet known if ICI 182780 is effective in preventing breast cancer metastases. PURPOSE: Randomized phase III trial to study the effectiveness of ICI 182780 given before surgery in treating women who have stage I or stage II primary breast cancer.
NCT00012025 ICI 182780 in Treating Women With Metastatic Breast Cancer Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 may fight breast cancer by blocking the activity of estrogen in the tumor cells. PURPOSE: Phase II trial to study the effectiveness of ICI 182780 in treating patients who have metastatic breast cancer that has not responded to previous hormone therapy.
Trial ID Title Status Sponsor Phase Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for FASLODEX

Condition Name

Condition Name for FASLODEX
Intervention Trials
Breast Cancer 41
Metastatic Breast Cancer 21
Breast Neoplasms 9
Stage IV Breast Cancer 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for FASLODEX
Intervention Trials
Breast Neoplasms 101
Neoplasms 7
Carcinoma 7
Carcinoma, Ductal 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for FASLODEX

Trials by Country

Trials by Country for FASLODEX
Location Trials
United States 421
Italy 75
Canada 43
Japan 37
Spain 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for FASLODEX
Location Trials
California 22
Texas 22
Florida 21
New York 21
Missouri 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for FASLODEX

Clinical Trial Phase

Clinical Trial Phase for FASLODEX
Clinical Trial Phase Trials
Phase 4 2
Phase 3 23
Phase 2 67
[disabled in preview] 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for FASLODEX
Clinical Trial Phase Trials
Completed 33
Active, not recruiting 27
Not yet recruiting 21
[disabled in preview] 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for FASLODEX

Sponsor Name

Sponsor Name for FASLODEX
Sponsor Trials
AstraZeneca 46
National Cancer Institute (NCI) 14
Pfizer 10
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for FASLODEX
Sponsor Trials
Other 98
Industry 90
NIH 15
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Queensland Health
Accenture
Teva
Argus Health
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.